Focusing on both clinical and basic research, topics will focus on cutting edge science in the field.
San Diego, California (PRWEB) November 23, 2014
Formerly known as the International Symposium on Anti-Angiogenic Agents, The 17th Annual Symposium on Anti-Angiogenesis and Immune Therapies for Cancer: Recent Advances and Future Directions in Basic and Clinical Cancer Research will take place in sunny La Jolla, California on February 19 -21, 2015.
Focusing on both clinical and basic research, topics will focus on cutting edge science in the field, highlighting novel strategies under both pre-clinical and clinical development, and include:
- Rationale for and mechanisms of action of novel anti-angiogenic and immune-targeted strategies
- Stromal therapy and targets in the tumor microenvironment
- Combination regimens
- Controversies with the new therapeutics, mechanisms of resistance, unique adverse events, and ongoing clinical trials
- Poster presentations
This symposium is designed for medical, surgical, and radiation oncologists, pharmacists, other healthcare providers (physician assistants, nurses, nurse practitioners), and research scientists who have an interest in the biology, diagnosis, and treatment of cancer, as well as those who diagnose and treat patients with nonmalignant vascular diseases.
One of the goals of the conference is to present the best new scientific research and advance knowledge on the state of the science. Health care professionals are invited to share their research initiatives with the community by submitting an abstract. Details can be found at http://www.antiangioimmuneconference.com. Abstracts are subject to acceptance by the Scientific Committee and should be submitted by December 22, 2014.
The outstanding faculty is comprised of over 35 expert specialists and co-chaired by George W. Sledge, Jr., MD; Robert S. Kerbel, PhD; Lee M. Ellis, MD; Axel Grothey, MD; Helen X. Chen, MD; and Elizabeth M. Jaffee, MD. Through didactic presentations, interactive panel discussions, and Q&A sessions, the conference will serve as a platform to discuss and evaluate many of the basic research and clinical challenges for optimal integration of antiangiogenesis and immune-modulating agents into existing treatment paradigms for cancer care, appropriate selection of patients based on biomarker profiles for individualized treatment strategies, and use of these agents in the adjuvant and advanced disease settings.
Imedex is an industry leader in providing accredited, independent continuing medical education to health care professionals. We develop high quality scientific programming that translates the latest research into clinically relevant information. The activities have exceptional organization and outstanding educational value, with a proven sustained impact on disease management.
Our programs focus on improving patient care around the world. With over 50,000 e-learning experiences annually and more than 100,000 live meeting attendees since 2001, Imedex truly educates the global healthcare community. At Imedex, education is the best medicine.®